Article Text
Editorial
Patients with atrial fibrillation and coronary events: are we any closer to coming out from the labyrinth of the various antithrombotic strategies?
Statistics from Altmetric.com
Footnotes
Competing interests GP: speaker/consultant/advisory board for Amgen, Sanofi, Bayer, Boehringer-Ingelheim, BMS-Pfizer, Daiichi Sankyo, Astra Zeneca, Sigma-Tau, Malesci, PIAM and MSD.
Provenance and peer review Commissioned; internally peer reviewed.
Linked Articles
- Arrhythmias and sudden death